(PGEN) Precigen, Inc. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(PGEN) Precigen, Inc. Complete Analysis Pack
Download Your Competitive Advantage
This Precigen, Inc. BCG Matrix is a company-specific strategy tool used to assess how its products or business units fit into Stars, Cash Cows, Question Marks, and Dogs. The page already shows a real preview of the analysis, so you can see the actual format and content before buying. Purchase the full version to get the complete ready-to-use report.
Stars
PAPZIMEOS, FDA-approved Aug 2025
PAPZIMEOS, approved by the FDA in August 2025, is Precigen, Inc.'s first approved product and the first approved therapy for adult recurrent respiratory papillomatosis. That makes it the clearest "Star" in Precigen, Inc.'s portfolio, with a strong high-share launch setup in a new niche market. Commercial uptake through late 2025 is the key growth driver, and early U.S. launch execution should matter most for revenue ramp.
Adult recurrent respiratory papillomatosis, 1 approved indication
Adult recurrent respiratory papillomatosis is a rare, specialist-led niche, and Precigen has no approved direct competitor, so share capture can be high. The market is still underpenetrated because diagnosis, referral, and reimbursement are uneven, which gives the franchise room to scale. At end-2025, this is Precigen's core Star asset: one approved indication with the clearest path to growth.
Zopapogene imadenovec-drba, first commercial gene therapy
In August 2024, the FDA approved Zopapogene imadenovec-drba, giving Precigen, Inc. its first commercial gene therapy and moving it from development-stage to marketed-stage biotech. As Precigen, Inc.'s only commercial product in 2025, it needs heavy sales, physician education, and access spending at launch, but if adoption holds it can become the company’s main cash driver.
Specialty launch model, late-2025 commercialization
Precigen’s late-2025 launch of PAPZIMEOS for recurrent respiratory papillomatosis is a classic specialty move: a rare-disease market with concentrated ENT adoption and premium pricing. The FDA approved it in August 2024, and with only about 27,000 U.S. patients living with RRP, first-mover share can build fast, which fits a star profile better than a broad-market launch.
- Rare-disease base: about 27,000 U.S. patients
- FDA approval: August 2024
- Commercial model: focused specialist adoption
- Star case: small market, fast share gains
First-to-market RRP franchise, 2025
Precigen entered 2025 with no approved product and exited with one: PAPZIMEOS, the first FDA-approved therapy for recurrent respiratory papillomatosis in adults. In a niche orphan market with roughly 27,000 U.S. patients, first-to-market status matters because it can lock in prescriber habits, support follow-on sales, and open label expansion. This is the portfolio’s strongest growth-and-share mix.
- 2025: 0 approved products to 1
- First FDA approval in RRP
- Orphan base supports expansion
PAPZIMEOS: Precigen’s First Big Growth Engine
PAPZIMEOS is Precigen, Inc.'s clearest Star: the first FDA-approved therapy for adult recurrent respiratory papillomatosis, with about 27,000 U.S. patients and no direct approved rival. Its 2025 launch gives Precigen, Inc. a rare high-share, high-growth asset, but uptake, reimbursement, and specialist adoption will decide how fast it scales.
| Key Star facts | Data |
|---|---|
| FDA approval | August 2024 |
| U.S. patient base | ~27,000 |
| Status in 2025 | Only commercial product |
What is included in the product
Detailed Word Document
Precigen’s BCG Matrix maps its gene-editing pipeline and commercial assets to spot stars, cash cows, question marks, and dogs.
Editable Excel File
Quick BCG Matrix for Precigen, Inc. to pinpoint winners, laggards, and next moves.
Reference Sources
Provides a credible source trail for Precigen, Inc. that helps validate assumptions, support decisions, and speed due diligence.
Cash Cows
Sleeping Beauty transposon system, mature platform
Sleeping Beauty is one of Precigen, Inc.’s oldest core enabling platforms, and it has supported cell and gene engineering collaborations for years. Mature platform IP usually needs less incremental development spend than new drug programs, so it can act as a steadier licensing asset. That fits a Cash Cow profile: lower upkeep, repeat use, and recurring partner value.
RheoSwitch inducible gene switch, legacy licensing asset
RheoSwitch is a long-established gene-control platform, and in FY2025 it fits Cash Cow logic because value comes from partner licensing, not heavy internal spend. Mature platform deals can bring recurring fees with limited growth capex, so the asset can keep throwing off cash even without major commercialization push. That is steady, low-growth, high-margin behavior.
UltraVector DNA design platform, established infrastructure
UltraVector is a cash cow style asset because it is a platform, not a single drug bet, so one design engine can support multiple partner programs over time. That lowers program-by-program risk and can create steadier fee, milestone, and licensing economics than development-stage therapeutics. Precigen, Inc. can reuse this infrastructure across many gene construct builds, which tends to keep returns more predictable.
AttSite recombinases, precision DNA toolset
AttSite recombinases fit Precigen’s cash-cow logic because they are a mature platform tool that supports partner deals and internal engineering without needing heavy launch spend. In a 2024 filing, Precigen still relied on collaboration and licensing-style value, while the platform kept advancing programs like site-specific DNA editing. That makes AttSite more of a low-capex cash engine than a standalone commercial bet.
It can monetize through upstream use in partner programs, so margin pressure is lower than for a drug launch. One clean read: platform IP can pay before products do.
- Enables partner programs
- Supports internal R&D use
- Low commercialization spend
- Cash-flow friendly platform asset
Partnered license portfolio, Ares Trading and others
Precigen’s partnered license portfolio with Ares Trading, Alaunos, Oragenics, and Castle Creek fits Cash Cows because it can bring in non-product cash and strategic support without heavy launch spend. These deals are lower-growth than its core therapeutics, but they can still help fund operations while the pipeline scales.
- Licenses can produce fee and milestone income
- Partner funding reduces Precigen cash burn
- Lower growth, but steady operating value
Precigen’s FY2025 Cash Cows: Mature Platforms Power Steady Value
In FY2025, Precigen, Inc.’s Cash Cows are its mature platform assets, especially Sleeping Beauty, RheoSwitch, UltraVector, AttSite, and legacy partner licenses. They fit the model because they can keep producing licensing, collaboration, and milestone value with limited launch spend, so they support cash flow more than growth.
| Asset | FY2025 Cash Cow Read |
|---|---|
| Sleeping Beauty | Mature platform IP; repeat partner use |
| RheoSwitch | Licensing-led, low incremental spend |
| UltraVector | Reusable engine for partner programs |
| AttSite | Engineering tool with low commercialization cost |
Preview Before You Purchase
Precigen, Inc. Reference Sources
The Precigen, Inc. BCG Matrix preview you’re seeing is the exact same document you’ll receive after purchase. No watermarks, no demo pages—just the complete, professionally formatted report. It’s ready to download and use right away for analysis or presentation.
Dogs
Intrexon Energy Partners I, legacy venture
Intrexon Energy Partners I is a legacy venture, not a 2025 growth engine for Precigen's gene-therapy focus. It sits outside the core pipeline and can still pull time and oversight without clear upside, which fits a Dog profile. In a portfolio built around clinical assets, a non-core structure with limited strategic relevance belongs on the bottom-right of the BCG Matrix.
Intrexon Energy Partners II, legacy venture
Intrexon Energy Partners II is a legacy holdover, not part of Precigen, Inc.'s core biotech growth engine. It does not support the 2025 commercialization story, and with 2 legacy energy partnerships already outside the main strategy, the fit is weak. Low strategic fit and limited growth make it a clear dog, so capital and management attention should stay minimal.
Genetically engineered swine, niche regenerative medicine
Precigen’s genetically engineered swine work sits in a narrow regenerative-medicine niche, not a broad commercial franchise. It has not scaled into a major revenue driver, while Precigen’s oncology programs carry the main growth story. Small market size and slow adoption make this a dog-like use of capital.
Advanced reproductive and embryo transfer technologies, small niche
Precigen, Inc.’s advanced reproductive and embryo transfer work is real, but it is still a niche side business in 2025, not the main value driver. The company’s growth story is tied to its FDA-approved therapeutics, especially its 1 approved commercial asset, while this area stays low-share and low-growth.
- Real, but not core to 2025 value
- Specialized market, limited expansion
- Far from FDA-led growth
- Fits "dog" BCG traits
So, in BCG terms, this looks like a low-share, low-growth asset with limited strategic pull. It may have technical value, but it does not move Precigen, Inc.’s 2025 financial story.
ActoBiotics legacy programs, limited traction
Precigen, Inc.'s ActoBiotics platform has stayed in the portfolio for years, but by end-2025 it was still not the company’s main commercial engine. Adoption looks limited, and revenue scale remains uncertain, which fits a Dog in the BCG matrix. That makes it a clear candidate for deprioritization unless new licensing or clinical traction changes the case.
- Legacy platform, not a growth driver.
- Limited adoption signals weak demand.
- Revenue scale remains unclear.
- Best fit: deprioritize or exit.
Precigen’s Legacy Assets Remain Low-Growth Dogs
Precigen’s Dogs are mostly legacy, low-growth assets: 2 Intrexon Energy Partners, ActoBiotics, and niche non-core programs. In 2025, Precigen’s value still centered on 1 approved commercial asset, so these units added little growth or cash. They fit the BCG Dog box: low share, low growth, and weak strategic pull.
| Dog asset | 2025 status | Fit |
|---|---|---|
| Intrexon Energy Partners I/II | Legacy holdovers | Dog |
| ActoBiotics | Limited adoption | Dog |
| Niche biotech programs | Small scale | Dog |
Question Marks
PRGN-2009, HPV16 cancer immunotherapy
PRGN-2009 is a clinical-stage AdenoVerse immunotherapy for HPV16-driven cancers, so it sits in the Question Mark bucket: high growth potential, low market share today. HPV16 drives about 70% of cervical cancers and a large share of head and neck cancers, keeping the unmet-need pool big. But Precigen, Inc. has not yet shown commercial traction, so the payoff is still clinical, not proven.
PRGN-3005, UltraCAR-T for ovarian cancer
PRGN-3005, UltraCAR-T for ovarian cancer, is still a development-stage cell therapy in a big cancer market. Global ovarian cancer burden was about 314,000 new cases and 207,000 deaths in 2022, and relapse after standard therapy remains common. That supports upside if efficacy holds, but the program has no market share yet and needs major clinical proof to move out of question-mark status.
PRGN-3006, UltraCAR-T for AML
AML remains a high-value hematology oncology market with strong unmet need; the American Cancer Society estimated about 20,800 new U.S. AML cases in 2024, and relapse options stay limited. Precigen's UltraCAR-T, including PRGN-3006, is differentiated by its non-viral, faster manufacturing design, but it is still investigational and not a commercial winner. It stays a question mark until late-stage data show durable efficacy and safety.
Next-generation UltraCAR-T pipeline, solid tumors
Precigen, Inc.'s next-generation UltraCAR-T solid-tumor pipeline fits a Question Mark in the BCG Matrix: the market is large and growing, but share is still near zero and clinical win rates in solid tumors remain low. This is a long-shot growth bet, not a cash engine, and it needs heavy R&D spending to avoid slipping toward Dog status.
- High-growth space, low proven success
- Near-zero share today
- Needs sustained funding
ActoBiotics therapeutic bacteria pipeline, early stage
ActoBiotics is still a pre-commercial, early-stage platform built for mucosal delivery using engineered bacteria, so it has long-term upside but no proven market win yet. That makes it a classic question mark in Precigen, Inc.'s BCG matrix: high potential in a fast-moving biologics niche, but weak current scale and no dominant commercial position.
Its value is tied to future clinical and partnership progress, not today’s sales.
Pre-commercial platform
Mucosal delivery focus
Engineered bacteria approach
High upside, low market share
Precigen’s High-Need Oncology Bets Still Await Proof
Precigen, Inc.'s Question Marks are mostly pre-revenue oncology bets: PRGN-2009, PRGN-3005, AML UltraCAR-T, and ActoBiotics. They target large, high-need markets, but none has commercial share yet, so value still depends on trial wins.
HPV16 causes about 70% of cervical cancers, and global ovarian cancer cases were 314,000 in 2022, but Precigen, Inc. has not shown sales traction.
These programs need capital and late-stage data before they can move out of Question Mark status.
| Program | Status | Key data |
|---|---|---|
| PRGN-2009 | Question Mark | HPV16 |
| PRGN-3005 | Question Mark | 314,000 ovarian cases |
| ActoBiotics | Question Mark | Pre-commercial |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.